Home
About us
Annual Meeting Abstracts
Annual Meeting
Annual Meeting

Annual Meeting Abstracts

24th Annual Meeting of the Japanese Society of Clinical Neuropsychopharmacology
jointly with 44th Annual Meeting of Japanese Society of Newropsychopharmacology

November 20-22, 2014
Nagoya Congress Center

FIRST AUTHOR INDEX
Last Name First Name No. Title
Harvey Philip SL-1 Newest Developments in the Assessment and Treatment of Cognition and Disability in Schizophrenia
Manji Husseini K. SL-2 Targeting Synaptic & Neural Plasticity to Develop Improved Rx’s for Severe Mood Disorders
Kim Hyoung-Chun S10-1 Role of IL-6 in the neurotoxicity and cognitive dysfunction induced by convulsant
Saito Kuniaki S10-2 The role of L-tryptophan metabolism via indoleamine 2,3-dioxygenase on cytokine-induced depressive symptoms
Yamada Kiyofumi S10-3 Molecular mechanism of neurodevelopmental disorders associated with perinatal aberrant neuroimmune responses
Niwa Minae S10-4 Dopaminergic disturbance and behavioral deficits in mental illness: Roles of stress and glucocorticoids
Kato Takahiro S10-5 Psychosocial stress and microglia-translational research focusing on human microglia
Kimura Hiroshi PJ-1 A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis
Takeuchi Hiroyoshi PJ-2 Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients with Schizophrenia: An Open-label, Randomized, Controlled, Pilot Study
Suzuki Yutaro EN-3 Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia
Harvey Philip LS07 The Role of the dopamine D3 receptor in Cognition and Disability in Schizophrenia
Andersen Peter Høngaard AS01 Development of the curative medicine to the psychiatric disorders (especially depression, mood disorders) by industrial, administrative and academic sectors cooperation
Kane John M. SpS4-1 Consider the therapeutic goals: Recovery
Tsuboi Takashi O1-E2 Challenging the Need for High and Sustained Dopamine D2 Receptor Blockade in the Maintenance Treatment of Schizophrenia: A Single-Blind, Randomized, Controlled Study
Ishioka Masamichi O1-F6 Hyperprolactinemia during antipsychotic treatment increases the risk for venous thromboembolism
Tsuneyama Nobuto O1-F7 Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia
Shinfuku Masaki O1-F9 Effectiveness of Long-term Benzodiazepine Use in Anxiety Disorders: A Systematic Review
Moriya Shunpei O3-F2 Effect of quetiapine on Per1, Per2, and Bmal1 clock gene expression in the mouse amygdala and hippocampus
Odagaki Yuji O3-F9 Selective interaction between adenosine receptors and Gi-3 in postmortem human brain membranes
Mizoguchi Kazushige O3-F13 Specific binding and characteristics of 18β-glycyrrhetinic acid in the rat brain
Kato Masaki P1-1 Genome-wide interaction and pathway analysis on SSRI response in Japanese patient with major depression
Matsumoto Yoshihiko P1-4 Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder
Kishi Taro P1-7 The Position of Blonanserin as a Treatment for Schizophrenia
Kishi Taro P1-8 Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials
Harvey Philip P1-13 IMPACT OF IMPROVED INSIGHT IN SCHIZOPHRENIA: A DOUBLE-BLIND LURASIDONE AND QUETIAPINE XR STUDY
Oya Kazuto P1-19 Efficacy and Tolerability of Minocycline Augmentation Therapy in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Oya Kazuto P1-20 Efficacy and Tolerability of Histamine-2 Receptor Antagonist Adjunction of AntipsychoticTreatment in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Uchida Hiroyuki P1-22 Dose and Dosing Frequency of Long-Acting Injectable Antipsychotics: A Systematic Review of PET and SPECT Data and Clinical Implications
Siu Cynthia P1-26 Insight into illness and uncooperativeness in chronic schizophrenia
Suzuki Yutaro P1-32 Effects of olanzapine on the PR and QT intervals in patients with schizophrenia
Saito Mami P1-39 High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia
Tarumi Ryosuke P1-43 The evolution of augmentation therapy in the treatment of depression: a chart review
Ueno Fumihiko P1-45 Whether to increase or maintain dosage of mirtazapine in early non-improvers with depression
Yoshida Kazunari P1-50 Population pharmacokinetic analysis of lithium: a preliminary study
Matsunaga Shinji P1-59 Memantine Monotherapy for Alzheimer's disease: A Systematic Review and Meta-analysis
Sasaki Tsuyoshi P1-63 Tipepidine in children with attention deficit/ hyperactivity disorder: a 4-week, open-label, preliminary study
Ogasa Masaaki P1-95 VALIDITY CHARACTERISTICS OF COGNITIVE ASSESSMENT INTERVIEW (CAI) IN STABLE OUTPATIENTS WITH SCHIZOPHRENIA
Mizoguchi Kazushige P2-19 Specific binding and characteristics of geissoschizine methyl ether, an alkaloid of Uncaria Hook, in the rat brain
Oshibuchi Hidehiro P2-39 CHRONIC HYPOACTIVITY OF RAPHE SEROTONERGIC NEURONS INHIBITS COCAINE SENSITIZATION; A STUDY USING DESIGNER RECEPTORS EXCLUSIVELY ACTIVATED DESIGNER DRUGS
Shimizu Kunio P2-41 Environmental Enrichment enhances hippocampal autophagy signaling in a rat animal model of posttraumatic stress disorder using a shuttle box
Nagasawa Sarah P2-42 The effectiveness of methylphenidate and atomoxetine in the dopamine transporter knockout (DAT-KO) mice by postnatal development
Moriguchi Shigeki P2-44 Function of decreased Na+/Ca2+ exchanger type 2 in AD model mice
Yamada Makiko P2-53 Effects of escitalopram on the amygdala dopamine release in the stress-sensitive rats
Mizuno Yuya P2-66 Biological and Clinical Correlates of Resilience in Patients with Schizophrenia: A Cross-sectional Study


Jscnp Japanese